Minister of Defence Rajnath Singh today visited the Institute of Aerospace Medicine (IAM) of the Indian Air Force (IAF) in Bengaluru, where he met with the officers from the IAF. He drew attention to the increasing
Lupin Ltd has rolled out the reviroxaban tablet, 2.5 mg, in the US market. This comes after the FDA gave its final nod to the company's abbreviated new drug application on March 7. The product matches the generic version...
Civica, a non-profit generic drug and pharmaceutical company established in 2018 to address and resolve life-saving drug shortages and affordability, and Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Bioc
Belgium-based Quantoom Biosciences (Quantoom) and TechInvention Lifecare Pvt. Ltd. (TechInvention) have launched a strategic partnership. In the presence of Her Royal Highness Princess Astrid of Belgium, business executives, and important...
Prime Minister Narendra Modi stated that the pharmaceutical business in India is poised for significant expansion, with its valuation anticipated to increase from ?4 lakh crore to ?10 lakh crore due to improved collaboration between the private secto
Gentium Capital LLP, a global private equity firm, has opened its first office in Pune, marking the start of a major expansion into India's rapidly growing market. The firm has unveiled a $5 billion investment plan for the next five years, focusing..
India is fast emerging as a key hub for Global Capability Centers (GCCs), changing the way businesses do their work globally. Digital transformation and rapid advancements...
The Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India, has granted AstraZeneca Pharma India permission to import pharmaceutical formulations of new drugs for sale or distribution of oral
Wipro GE Healthcare has launched the Versana Premier R3. This is an AI-enabled ultrasound system designed to enhance...
The Indian pharmaceutical sector is witnessing a major advance. Zydus Lifesciences is launching ANVIMO, a cost-effective substitute for the prevention of Cytomegalovirus (CMV) disease in haematopoietic stem cell transplant (HSCT) and kidney transplan
, CDSCO.jpg)
